Systemic Anti Cancer Therapy (SACT) Patient Information leaflets

A

• Abemaciclib A1172
• Abiraterone
• Abraxane 485 & 489
• Adjuvant Abemaciclib A1540
• Alpelisib A1332
• Apalatumide A1236
• ABT 414 (Abbvie)
•  
• Afatinib 618
• Aflibercept & irinotecan, 5 fluorouracil (5-FU) and folinic acid
• Alectinib (A1102)
• Atezolizumab A1698
• Atezolizumab and Bevacizumab A1705
• Atezolizumab and Abraxane A1701
• Avelumab A1065 and A1520
• Axitinib 665

B

• Bendamustine 533
• BEP 67
• Bevacizumab 346
• Binimetinib and Encorafenib 

C

• Caelyx 309
• Caelyx and carboplatin 413
• Cabazitaxel 755
• Cabozantinib - 979 and A1113
• Capectabine - 236
• Capecitabine with RT 325 and 67
• Capecitabine and mitomycin and RT 631
• Capecitabine and mitomycin 327
• Oxaliplatin and capecitabine 289 and 324 and A1197
• Capecitabine and Temozolamide 822
• Capecitabine and Tucatinib A1507
• Carboplatin 5 and 205
•  Carboplatin and Abraxane A1615
• Carboplatin and Taxol
• Carboplatin and Capecitabine 373 and 608
• Carboplatin and docetaxel 167
• Carboplatin and etoposide 103 and 321
• Carboplatin - testicular cancer 91
• Carboplatin and vinorelbine 514 &515
• Carboplatin and 5FU
• CAV
• CCEP 248
• Cemiplimab A1199
• Ceritinib 978
• Cetuximab 340
• Cetuximab with oxaliplatin 5FU and folinic acid 578
• Cetuximab and cisplatin 5FU A1027
• Cisplatin
• Cisplatin and capecitabine RT 363
• Cisplatin and capecitabine chemotherapy 363
• Cisplatin and capecitabine (head and Neck) 458
• Cisplatin and 5FU (Radiotherapy) 201
• Cisplatin and 5FU 158 A1232
• Cisplatin & etoposide 450
• Cisplatin and gemcitabine 292 and 358
• Cisplatin and RT 180 and 243
• Cisplatin and vinorelbine 571
• Cisplatin and teysuno 857
• CMF - Available from Macmillan
• Continual infusion 5FU and mitomycin
• CVP 232

D

• Dabrafenib 850
• Dafrabanib & Trametinib 784 A1119
• Dacarbazine 195
• Denosumab 656
• Docetaxel 78, 347 ,361, A1518 , A1519 & A1625
• Docetaxel and cyclophosphamide TC 479
• Docetaxel and nintedanib 907
• Docetaxel and OxMdG1 A1042
• Dostarlimab A1503
• Doxorubicin 82
• DPD testing for patients receiving 5FU or Capecitabine
• Durvalumab A1048

E

• EcarboF 377
• EcarboX 374
• ECF 4
• ECF 362
• EC-T
• ECX 277
• Encorafenib and Binimetinib
• Encorafenib and Cetuximab A1294
• (Enhertu®) Trastuzumab deruxtecan
• Entrectinib A1254
• Enzalutamide 690
• Epirubicin, Carboplatin, Paclitaxel, Cyclophosphamide and Pembrolizumab 547, A1023, A1600 and A1162
• Epirubicin, Cyclophosphamide and Paclitaxel A1023, A1601, A1228, A1229
• Erlotinib (Tarceva) 449
• Eribulin 647
• Etoposide 338
• Etoposide, Doxorubicin and Cisplatin chemotherapy 670
• EOX 276
• Everolimus 484
• Extravasation 

F

• FEC 14 and 422
• FEC-T 388 and 476
• Weekly 5FU

G

• Gemcitabine 244 and 81
• Gemcitabine and abraxane 793
• Gemcitabine and docetaxel 597
• Gemcitabine and carboplatin 322
• Gemcitabine and capecitabine 320
• Gem-P 456
• General Chemotherapy (pdf file format)

H

• Herceptin (subcutaneous) 786
• How to take capecitabine tablets (Visual guide pdf)
• Hair Loss Leaflet

I

• IrOxMdG 526 and A1237 (Folfinirnox)
• Imatinib 333
• Interferon 406
• Ipilimumab 589
• Ipilimumab and nivolumab 969 and A1078
• IAd 43
• IrMdG 179
• IrMdG and Cetuximab 527
• Irinotecan 342 & 341
• Idelalisib 882
• Irinotecan and Vincristine
• Irinotecan and capecitabine

J

• -

K

• Kadclya® (Trastumzumab Emtansine) 

L

• Lenvatinib 977
• Pembrolizumab and Lenvatinib A1553
• Lorlatanib A1137
• Lonsurf (Taas-102) 940

M

• Macmillan Cancer Unit - Prince Charles Hospital - Merthyr
• Masitinib 819
• Mifamurtide 645
• Mitomycin and (5-FU) with radiotherapy 264 and 910
• Modified deGramont 175
• MV Carbo 328

N

• Nevill Hall - Outreach Clinic
• Niraparib A1034
• Nivolumab 932, A1070 and A1118

O

• Olaratumab and doxorubicin 987
• Oxaliplatin and raltitrexed 561
• Oxaliplatin, 5-FU and folinic acid 178
• Olaratumab and doxorubicin
• Osimertinib 926
• Olarparib 899
• Oxaliplatin and capecitabine 289, 324 and A1197

P

• Paclitaxel 402,242 & 662
• Palbociclib 949
• Panitumumab with oxaliplatin,  5 fluorouracil and folinic acid (OxMdG) A1047
• Pembrolizumab and Lenvatinib A1553
• Pemetrexed
• Phesgo
• Pixantrone
• Pazopanib
• Pemetrexed and carboplatin 570
• Pembrolizumab 836
• Pembrolizumab, Paclitaxel, Carboplatin, Epirubicin and Cyclophosphamide,  547, A1023, A1600, A1162
• Pemetrexed and cisplatin 354
• Princess of Wales
• Procarbazine, lomustine and vincristine 95 (PCV)
• PICC line - Securacath

Q

• -

R

• Regorafenib 717
• Ribociclib A1043
• Ramucirumab 917
• Royal Glamorgan Hospital
• R Bendamustine 773
• R-CHOP
• Rucaparib A1069

S

• Sacituzumab Govitecan (Trodelvy®) 
• Scalp Cooling
• Sorafenib
• St David's Hospice (Newport)
• Subcutaneous herceptin 786
• Sunitinib
• Switch from hercepting to Ontruzant

T

• Taxol 402, 242 & 662
• Taxol and Carboplatin 54
• Taxol and Ramucirumab 985
• Temozolomide 329 and 355
• Tivozanib A1061
• Topotecan
• Topotecan and Cisplatin 860
• TPF 415 (inpatient)
• Trabectedin 330 and 668
• Trastuzumab and Pertuzumab 748, A1092 A1093
• Trastuzumab deruxtecan (Enhertu®)
• Kadclya® (Trastuzumab Emtansine) 
• Trastuzumab 315, A1109, A1110, A1111, A1112
• T carbo F 679
• Transport - patient
• Trodelvy Sacituzumab Govitecan A1421
• Tucatinib and Capecitabine A1507

U

• -

V

• VAI (external CRUK leaflet)
• VIDE 224
• Vinorelbine 356

W

• Weekly 5FU 209

X

• -

Y

• -

Z

• Zometa 269
• Zometa early breast cancer A1057
• Zomorph - Capsules for oral and NG administration - Directions for opening